Following the acquisition of facility assets from the bankrupt Azzur Group, Chrysalis has opened three novel cleanroom facilities in Massachusetts and North Carolina, US.
The GMP-compliant cleanrooms are designed to help life science and biopharmaceutical companies accelerate the development of transformative therapies, offering flexible manufacturing services in line with specific project needs and milestones.
This comes at a time where there's increasing pressure to progress quickly through key development milestones.
According to the company, its cleanrooms will enable customers to retain full ownership of their programmes, while minimising expenditure.
“Our model is particularly valuable for programmes where retaining process control, protecting IP and minimising risk are crucial considerations,” said Sarah Stevens, CEO of Chrysalis.
“Our approach gives our customers flexibility to take only the space and services they need, when they need it by providing rapid access to GMP-compliant space and operational support."
"By offering these services, we hope to empower customers to advance on their own terms, transforming scientific promise into real progress without the burden of scheduling constraints or unnecessary ongoing expense,” she added.
The company partners with a wide spectrum of life science clients, including early-stage biotech companies, top pharmaceutical firms, contract research organisations (CROs) and other life science stakeholders.
Capable of handling a range of therapeutic modalities and technical needs, Chrysalis can help clients to maintain control and adapt quickly as their programmes evolve.
“Whether clients are navigating early development or preparing for commercialization, we’re here to grow with them. We don’t just provide space, we build partnerships grounded in collaborative operational excellence and a deep understanding of what it takes to operate in a GMP environment,” Stevens concluded.